This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Biologics constitute a majority of the top selling drugs and represent one of the fastest growing segments of the overall pharmaceutical industry. In fact, the share of biologics in the overall pharmaceutical contract manufacturingmarket has increased from 16% in 2006 to over 25% in 2017.
Nano-based deliverysystems are on the rise, as they enable manufacturers to deliver therapeutic agents to specific targeted tissue in a more controlled manner. Data indicates that the global nanopharmaceutical drugsmarket size reached USD 53.85 Billion in 2021 and is expected to reach USD 102.4 Billion in 2030.
Contract marketing companies support pharmaceutical companies in creating, improving, and maintaining their brand, as well as reducing risk, and ensuring better product placement in the market. Identifying the top commercial dose (non-sterile) companies in contract marketing.
Further, most of the funding reported by intranasal therapeutics and drugdeliverysystems domain were secondary offerings. Intranasal Therapeutics and DrugDeliverySystems. The intranasal therapeutics and drugdeliverysystemsmarket is anticipated to grow significantly, during 2022-2035.
The overall manufacturing of oligonucleotides involves the following steps. Owing to the incessant demand for oligonucleotide-based products, several small to mid-sized companies and certain pharma giants, have begun outsourcing their manufacturing operations to contract service providers. Accelerating Oligonucleotide Demand.
Presently, outsourcing of exosome related services has become a popular practice where drug developers are actively outsourcing their operations to specialized repurposed-based service providers, which are known to have the required capabilities and expertise. Exosome Service Providers – Current Market Landscape. Web: [link].
When it comes to vaccines and other high-value biologics, it is essential that effective formulations go hand in hand with safe delivery. To boost the profitability of the drug at a later stage in its lifecycle, manufacturers may then consider changing the presentation to prefilled syringes. Lowering extractables levels .
Given the evident benefits of biologics over small molecule drugs (including high efficacy, target specificity and favorable safety profiles), the biopharmaceutical market is poised to witness continued and consistent growth over the next several years. As a result, the demand for biopharmaceutical excipients has grown considerably.
Highlights include expansion of biotech operations in Philadelphia, acquisition of a new pharma-device facility near Dublin, Ireland, and a new Center of Excellence for advanced drugdelivery and drug-device combination product assembly in Rockford, Illinois.
The current landscape consists of more than 95 players that claim to offer oligonucleotide contract manufacturing services for research, diagnostic and therapeutic applications. It is worth highlighting that major share of the global oligonucleotide manufacturing capacity is installed in North America, primarily in the US. Web: [link].
The healthcare industry has one of the heaviest environmental footprints, and manufacturers are increasingly faced with regulations to make more sustainable products,” said Mohammad H. The Global ECG Patch Market The global ECG patch and holter monitor market , estimated to be around $13 billion and projected to grow at a 17.5
Subcutaneous biologics – current market landscape. Subcutaneous drugdeliverysystems – the helping hand for patients. Many of these antibody-based products are highly viscous and need to be administered using deliverysystems in volumes that exceed the standard fill of a 1 mL prefilled syringe. Web: [link].
Role of nanoparticles has been well established across various markets, such as healthcare, paint, consumer products ( including sunscreens, cosmetics ), aerospace and glass industries. However, manufacturing of these particles is a major challenge for players engaged in the industry.
Recent years started witnessing the emergence of novel treatment approaches that have been keeping the Retinal vein occlusion market in a hyped-up state. Looking at the potential of the pipeline therapies they hold once approved, pharmaceutical companies are charting out a seemingly exciting course in the market.
Over the last two decades, the pharmaceutical industry has observed a paradigm shift from conventional drugdelivery strategies to the long-acting drugdelivery (LADD) of products to treat several disease indications, such as ophthalmic disorders, oncological disorders, neurological disorders and infectious diseases.
As a result, there is an evident increase in the demand for mRNA manufacturing capacity. The key applications of mRNAs are below: Contract Manufacturing in mRNA Synthesis AND Manufacturing Service Domain The synthesis and manufacturing process of mRNA-based therapeutics / vaccines is complex and associated with several challenges.
Presently, outsourcing of liposomes development and manufacturing related services has become a popular practice. Drug developers are actively outsourcing their operations to specialized repurposed-based service providers, which are known to have the required capabilities and expertise.
In earlier times, container closure integrity testing was not regarded as an essential step in the process of manufacturing. The company developing drug product through such an intense process, use to consider container closure system only for packaging of the product. [1] Container Closure Integrity Testing Services Market.
Owing to the numerous advantages of oral drugdelivery, including ease of administration, minimal pain and risk of drug reaction, and self-administration, we are led to believe that the oral protein / peptide therapeutics market is anticipated to witness a significant growth in the coming future. Web: [link].
XTALKS WEBINAR: ISO 11608: Best Practices to De-Risk & Shorten Time to Market for Wearable Injectors. Register for this free webinar to learn the best practices to successfully incorporate 2022 ISO 11608 methodology to mitigate risk and accelerate time to market in combination product development.
To learn more, please click New Frontiers Cancer Therapy market report. Types of Molecules and Regions Worldwide Overall, the growth is anticipated to be spread across multiple type of molecules and different geographical regions. For any queries / suggestions, please do not hesitate to contact us at sales@rootsanalysis.com.
Driven by lucrative investments, extensive R&D efforts and contributions from various big pharma players, the myeloid cell targeting therapeutics market is expected to grow at a steady pace. Myeloid Cells Targeting Therapeutics Market. Roots Analysis – MYELOID CELL TARGETING THERAPEUTICS: BUDDING THERAPY AGAINST CANCER.
Driven by the increasing need for safe and efficient medical devices and drugdeliverysystems, the pharmaceutical polymers / medical grade polymers domain is advancing significantly. There has been a rise in the development of polymers for biopharma with improved biocompatibility, biodegradability and functionality.
Next Generation Complement Therapeutics – Current Market Landscape. The market is characterized by a mix of well-established and small firms. The pipeline features more than 190 next generation complement therapeutics that are either marketed / are currently being evaluated across different phases of development. Web: [link].
The six-page statement explains that “Brand drugmanufacturers may be harming generic competition through the improper listing of patents in the. But it is not always clear which types of patents are eligible for listing in the Orange Book.
Metabolomics Services– Current Market Landscape. Considering the aforementioned factors, we are led to believe that the metabolomics services market is likely to witness rapid growth over the next few years. Therefore, unknown metabolite identification has a significant impact on omics research and biomarker discovery. Web: [link].
Conjugation with a Variety of Molecular Conjugates and Labels The combination of the conjugates / labels with molecules ( proteins, peptides, antibodies and small molecules ) is being used abundantly for several applications, ranging from therapeutics and diagnostics to isolation and characterization of drugdeliverysystems.
The LNPs can be monitored using various imaging modalities to confirm the delivery of siRNA to the target cells. This approach can enable synergistic effects, improved therapeutic outcomes, and reduced drug resistance.
They offer several advantages over traditional drugdeliverysystems ( such as vials and syringes ), including reduced chances of dosing errors, increased patient compliance and decreased risk of microbial contamination. Prefilled syringes are syringes that come pre-filled with a specific dose of medication.
Several drug development trends are driving injectables demand. This includes the rising number of biologic drugs on the market, which are mostly administered parenterally. The injectable drugsmarket is currently valued at around $532 billion.
While the industry is seeing advances in alternative drugdeliverysystems, oral solid doses, such as pills, capsules and soft gels, remain at the forefront of the industry. Compared to other dosage forms, tablets are simpler to manufacture, package, and transport.
This comprehensive guide will explore how pharmaceutical companies can leverage their drug patent portfolios to maximize value, maintain market dominance, and drive innovation. Understanding the Importance of Drug Patent Portfolios Drug patent portfolios are the lifeblood of pharmaceutical companies.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content